MASH — scarring fatty liver disease — has no FDA-approved drug treatment. A mid-stage trial of tirzepatide, the drug behind Mounjaro and Zepbound, showed real change on repeat biopsy. The resolution rates were larger than most GLP-1 trials produce.
MASH — metabolic dysfunction-associated steatohepatitis, the condition doctors used to call NASH — is fat buildup in the liver that has progressed to inflammation and cell injury. Left untreated, it can advance to fibrosis, cirrhosis, and eventually liver failure. It's estimated to affect roughly 1 in 20 US adults, disproportionately those with obesity or type 2 diabetes, and until recently no drug had regulatory approval specifically for the fibrosis stage of the disease.
Tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management — activates two gut-hormone receptors instead of one, GIP and GLP-1. Because both pathways influence fat metabolism and insulin sensitivity, researchers wanted to know whether that dual action would also show up in liver tissue, not just on the scale or in a blood sugar reading.
SYNERGY-NASH was a Phase 2, multicenter, double-blind, placebo-controlled trial that enrolled 190 adults with biopsy-confirmed MASH and stage 2 or 3 liver fibrosis — meaning scarring was already established, not just fatty change. Participants were randomized to once-weekly subcutaneous tirzepatide at 5 mg, 10 mg, or 15 mg, or to placebo, for 52 weeks. Everyone underwent a liver biopsy at baseline and again at week 52, so the results below are based on actual tissue samples, not blood markers alone.
The primary endpoint was resolution of MASH with no worsening of fibrosis at week 52:
A secondary endpoint tracked fibrosis specifically — at least one stage of improvement with no worsening of MASH:
All three doses beat placebo on both measures. Participants on tirzepatide also saw improvements in body weight, liver enzymes, and noninvasive imaging markers of liver fat. Adverse events skewed gastrointestinal — nausea, diarrhea, constipation — consistent with tirzepatide's known profile at these doses, and rates of serious adverse events or trial discontinuation were similar across all four arms, including placebo.
SYNERGY-NASH is Phase 2 evidence, not an approval. Neither Mounjaro nor Zepbound is currently FDA-approved to treat MASH — their approved uses remain type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea. Larger, longer Phase 3 trials would be needed before a liver-disease indication could be considered.
Sources: Loomba, Hartman, Lawitz et al., New England Journal of Medicine 2024;391(4):299–310, "Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis" (SYNERGY-NASH). See trial on PubMed and Eli Lilly results summary.
This is a mid-stage trial on a relatively small population — 190 people, one 52-week dosing period, no long-term outcomes like reduced cirrhosis or transplant rates reported yet. Biopsy improvement at one year is a real, meaningful signal, but it isn't proof the drug prevents liver failure over a decade.
MASH is frequently silent. Many people with stage 2–3 fibrosis have no symptoms and find out incidentally, through imaging or bloodwork ordered for something else. If you carry risk factors — obesity, type 2 diabetes, elevated liver enzymes on a routine panel — that's a conversation to have with your doctor, not something to self-diagnose from a trial summary.
Whether or not liver disease factors into your own treatment plan, consistency is still the part of the regimen you control day to day. GLP1ShotDay keeps the weekly shot on schedule, so that piece isn't one more variable to explain at your next appointment.
This article summarizes a single published Phase 2 trial for general education. It is not medical advice, and tirzepatide is not FDA-approved to treat MASH or liver fibrosis. Talk to your doctor about liver disease risk, testing, and treatment options.